The radiotherapy developer, which is exploiting UChicago research, has now raised $264m in funding overall.

Reflexion Medical, a US-based cancer therapy developer partially based on research at University of Chicago, completed a $100m funding round yesterday led by Canadian pension fund manager Public Sector Pension Investment Board. Pfizer Ventures and Johnson & Johnson Innovation – JJDC, subsidiaries of pharmaceutical firms Pfizer and Johnson & Johnson respectively, also took part in the round, as did KCK Group, Sofinnova Partners, Venrock, T. Rowe Price and TPG’s Rise Fund. Reflexion is developing biology-guided radiotherapy technology in an effort to create a system that will be able to treat multiple tumours simultaneously, even in cancers that have metastasized. The company secured marketing clearance from the US Food & Drug Administration for its Reflexion X1 system last month. The round increased Reflexion’s funding to approximately $264m since it was founded in 2009. It received $11.6m in series A funding from Pfizer Ventures, Sofinnova Partners and Venrock in 2014. Johnson & Johnson Innovation – JJDC invested $6m to help the company close a $52m series B round in 2016 also featuring KCK Group and all the series A investors. Rise Fund subsequently led Reflexion’s $100m series C round in 2018, investing alongside Pfizer Ventures, Johnson & Johnson Innovation – JJDC, T. Rowe Price, Sofinnova Partners, KCK Group, Venrock and GT Healthcare Capital Partners. – A version of this article first appeared on our sister site, Global Corporate Venturing.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?